ArriVent Biopharma
AVBP----
Eli Lilly To Rally Over 21%? Here Are 10 Top Analyst Forecasts For Thursday
benzinga_article·- Wall Street financial institutions have updated their ratings and price targets for several prominent companies. - Needham raised Everpure's target to $185, while HSBC downgraded Constellation Brands and cut its target to $135. - Cantor Fitzgerald boosted Eli Lilly's target to $1,440 and Amgen's target to $440 amid multiple analyst adjustments.ArriVent Retains Buy Rating as Analyst Sees Upside from Broader Pipeline Despite Trial Miss, Cutting Price Target to $22
Tip Ranks·- JonesTrading analyst Boris Peaker maintained a Buy rating on ArriVent BioPharma while lowering the price target to 22.00 dollars despite a recent Phase 3 clinical trial missing its primary endpoint. - The analyst noted that firmonertinib's progression-free survival aligned with prior predictions and emphasized that the company's broader pipeline offers significant upside potential with projected peak sales of approximately 1.3 billion dollars. - LifeSci Capital also maintained a Buy rating on the stock with a price target of 15.00 dollars.Crude Oil Edges Lower; Lamb Weston Shares Surge Following Upbeat Q1 Earnings
benzinga_article·- U.S. stocks traded higher on Tuesday, with the Dow Jones rising 0.69% to 51,622.17 and the S&P 500 gaining 0.86% to 7,840.48. - Lamb Weston shares surged approximately 12% following better-than-expected first-quarter financial results and an upgraded guidance for FY27. - The U.S. trade deficit widened to $105.6 billion in August, driven by a record high in imports reaching $420.8 billion.